Entera Bio Ltd.
ENTX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001638097
No open-market purchases or sales by Entera Bio Ltd. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $19.0M in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding Entera Bio Ltd. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 15 | 15 | 0 |
| Shares | 4.26M | 5.29M | +1.03M (+24.3%) |
| Value | $7.11M | $9.75M | +$2.63M (+37.0%) |
New holders (5)
Institutions that held Entera Bio Ltd. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Schonfeld Strategic Advisors LLC | 671,758 | $1.24M | 0.01% |
| Parkman Healthcare Partners LLC | 401,518 | $738.8K | 0.10% |
| CIBC World Markets Inc. | 12,500 | $23.0K | 0.00% |
| GWM Advisors LLC | 9,000 | $16.6K | 0.00% |
| Bank of America Corp | 3,000 | $5.52K | 0.00% |
Sold out (5)
Institutions that held Entera Bio Ltd. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Virtu Financial LLC | 22,040 | $37.0K |
| Millennium Management LLC | 19,510 | $32.6K |
| Citadel Advisors LLC | 12,502 | $20.9K |
| Royal Bank of Canada | 3,000 | $5.00K |
| JPMorgan Chase & Co | 2 | $3 |